Augmented reality: New tool may raise surgical accuracy

Cleveland-If you could see into a kidney, prostate gland, or bladder and know the extent of tumor penetration, the precise location of nerve bundles and blood vessels, or the exact depth and angle of your blade vis-?is the tumor at any given moment, how would it change surgery for you?

Related Videos

Related Content

Advertisement

February 18th 2025

PSMA staging is linked with higher rates of ADT, ARPI utilization in prostate cancer

Benjamin P. Saylor

PSMA staging did not appear to have a significant impact on radiation therapy utilization.

February 11th 2025

Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

February 18th 2025

RETAIN-2 interim data promising for dose-dense MVAC plus nivolumab in MIBC

Benjamin P. Saylor

“Among active surveillance patients, 82% are metastases free, and 60% were metastases free and had an intact, un-radiated bladder,” said Pooja Ghatalia, MD.

January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 17th 2025

Casdatifan is linked with promising safety, efficacy in clear cell RCC

Benjamin P. Saylor

“Over 80% of patients…had at least 2 lines of therapy, so this is a heavily refractory population,” said Toni K. Choueiri, MD, FASCO.

February 17th 2025

Anktiva under review in UK for BCG-unresponsive NMIBC with CIS

Hannah Clarke

Anktiva is also currently under review for the CIS indication in the EU.

Related Content

Advertisement

February 18th 2025

PSMA staging is linked with higher rates of ADT, ARPI utilization in prostate cancer

Benjamin P. Saylor

PSMA staging did not appear to have a significant impact on radiation therapy utilization.

February 11th 2025

Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

February 18th 2025

RETAIN-2 interim data promising for dose-dense MVAC plus nivolumab in MIBC

Benjamin P. Saylor

“Among active surveillance patients, 82% are metastases free, and 60% were metastases free and had an intact, un-radiated bladder,” said Pooja Ghatalia, MD.

January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 17th 2025

Casdatifan is linked with promising safety, efficacy in clear cell RCC

Benjamin P. Saylor

“Over 80% of patients…had at least 2 lines of therapy, so this is a heavily refractory population,” said Toni K. Choueiri, MD, FASCO.

February 17th 2025

Anktiva under review in UK for BCG-unresponsive NMIBC with CIS

Hannah Clarke

Anktiva is also currently under review for the CIS indication in the EU.